169 related articles for article (PubMed ID: 16337744)
41. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
42. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma.
Morinaga S; Tarao K; Yamamoto Y; Nakamura Y; Rino Y; Miyakawa K; Ohkawa S; Akaike M; Sugimasa Y; Takemiya S
J Gastroenterol Hepatol; 2007 Aug; 22(8):1249-55. PubMed ID: 17688665
[TBL] [Abstract][Full Text] [Related]
43. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
44. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
[TBL] [Abstract][Full Text] [Related]
45. New therapies for hepatocellular carcinoma.
Avila MA; Berasain C; Sangro B; Prieto J
Oncogene; 2006 Jun; 25(27):3866-84. PubMed ID: 16799628
[TBL] [Abstract][Full Text] [Related]
46. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
47. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
48. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
49. Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer?
Breinig M; Schirmacher P; Kern MA
Curr Pharm Des; 2007; 13(32):3305-15. PubMed ID: 18045183
[TBL] [Abstract][Full Text] [Related]
50. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
Repasky GA; Zhou Y; Morita S; Der CJ
Mol Carcinog; 2007 Dec; 46(12):958-70. PubMed ID: 17477350
[TBL] [Abstract][Full Text] [Related]
51. Hippo signaling in oval cells and hepatocarcinogenesis.
Zheng T; Wang J; Jiang H; Liu L
Cancer Lett; 2011 Mar; 302(2):91-9. PubMed ID: 21247686
[TBL] [Abstract][Full Text] [Related]
52. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
53. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
54. Signaling networks in human hepatocarcinogenesis--novel aspects and therapeutic options.
Breuhahn K; Schirmacher P
Prog Mol Biol Transl Sci; 2010; 97():251-77. PubMed ID: 21074736
[TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study .
Giannitrapani L; Ingrao S; Soresi M; Florena AM; La Spada E; Sandonato L; D'Alessandro N; Cervello M; Montalto G
Ann N Y Acad Sci; 2009 Feb; 1155():293-9. PubMed ID: 19250220
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of disease: Inflammatory mediators and cancer prevention.
Mann JR; Backlund MG; DuBois RN
Nat Clin Pract Oncol; 2005 Apr; 2(4):202-10. PubMed ID: 16264935
[TBL] [Abstract][Full Text] [Related]
57. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
Chi-Man Tang T; Tung-Ping Poon R; Fan ST
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S311-6. PubMed ID: 16507400
[TBL] [Abstract][Full Text] [Related]
58. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.
Geschwind JF; Georgiades CS; Ko YH; Pedersen PL
Expert Rev Anticancer Ther; 2004 Jun; 4(3):449-57. PubMed ID: 15161443
[TBL] [Abstract][Full Text] [Related]
59. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer.
Nikolaou K; Sarris M; Talianidis I
Clin Cancer Res; 2013 Jun; 19(11):2810-6. PubMed ID: 23549874
[TBL] [Abstract][Full Text] [Related]
60. Structural and regulatory aspects of enzymes in chemotherapy.
Handschumacher RE
Cancer Res; 1969 Dec; 29(12):2466-8. PubMed ID: 4313006
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
